Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olipudase Alfa Long-Term Follow-up in ASMD
NCT06949358Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2021
- Primary completion
- Apr 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of olipudase alfa in acid sphingomyelinase deficiency (ASMD), sponsored by Sanofi. Started Nov 2021; status: completed.
02
Drugs
olipudase alfa
03
Conditions
acid sphingomyelinase deficiency (ASMD)
Beyond the preview
Go deeper on NCT06949358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949358.